Hepatitis Monthly

Published by: Kowsar

Liver Cancer Mortality at National and Provincial Levels in Iran Between 1990 and 2015: A Meta Regression Analysis

Negar Rezaei 1 , Farshad Farzad Far 2 , Sara Khademiureh 2 , Ali Sheidaei 2 , 3 , Kimiya Gohari 2 , 3 , Farnaz Delavari 2 , Mahboubeh Parsaeian 2 , 4 , Alireza Delavari 5 , Mahtab Maghsoudlu 6 , Hamid Mohaghegh Shalmani 7 , Zahra Madadi 2 , Anita Mansouri 2 , Moein Yoosefi 2 , 3 and Mohsen Asadi-Lari 1 , 8 , *
Authors Information
1 Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, IR Iran
2 Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
5 Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran
6 Department of Research and Education and the, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
7 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
8 Oncopathology Research Centre, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: January 2018, 18 (1); e62009
  • Published Online: January 14, 2018
  • Article Type: Research Article
  • Received: September 20, 2017
  • Revised: October 31, 2017
  • Accepted: December 31, 2017
  • DOI: 10.5812/hepatmon.62009

To Cite: Rezaei N, Farzad Far F, Khademiureh S, Sheidaei A, Gohari K, et al. Liver Cancer Mortality at National and Provincial Levels in Iran Between 1990 and 2015: A Meta Regression Analysis, Hepat Mon. 2018 ; 18(1):e62009. doi: 10.5812/hepatmon.62009.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Palliyaguru DL, Wu F. Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(3):534-40. doi: 10.1080/19440049.2012.751630. [PubMed: 23281740].
  • 2. Fang JY, Wu KS, Zeng Y, Tang WR, Du PL, Xu ZX, et al. Liver cancer mortality characteristics and trends in China from 1991 to 2012. Asian Pac J Cancer Prev. 2015;16(5):1959-64. [PubMed: 25773794].
  • 3. Sengupta B, Siddiqi SA. Hepatocellular carcinoma: important biomarkers and their significance in molecular diagnostics and therapy. Curr Med Chem. 2012;19(22):3722-9. [PubMed: 22680921].
  • 4. G. B. D. Mortality , Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-544. doi: 10.1016/S0140-6736(16)31012-1. [PubMed: 27733281].
  • 5. Papaconstantinou I, Karakatsanis A, Gazouli M, Polymeneas G, Voros D. The role of microRNAs in liver cancer. Eur J Gastroenterol Hepatol. 2012;24(3):223-8. doi: 10.1097/MEG.0b013e3283505063. [PubMed: 22228372].
  • 6. (IHME) IfHMaE. GBD Compare. Institute for Health Metrics and Evaluation (IHME). Seattle, WA: University of Washington; 2015. Available from: http://vizhub.healthdata.org/gbd-compare.
  • 7. Tanaka K, Tsuji I, Wakai K, Nagata C, Mizoue T, Inoue M, et al. Alcohol drinking and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2008;38(12):816-38. doi: 10.1093/jjco/hyn108. [PubMed: 18945722].
  • 8. Park J, Jee YH. Age-Period-Cohort Analysis of Liver Cancer Mortality in Korea. Asian Pac J Cancer Prev. 2015;16(18):8589-94. [PubMed: 26745121].
  • 9. Marengo A, Rosso C, Bugianesi E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annu Rev Med. 2016;67:103-17. doi: 10.1146/annurev-med-090514-013832. [PubMed: 26473416].
  • 10. Liver (Hepatocellular) Cancer Screening (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002.(US) PCISIBMNCI; PDQ Screening and Prevention Editorial Board; (US) PCISIBMNCI; PDQ Screening and Prevention Editorial Board.
  • 11. Farzadfar F, Delavari A, Malekzadeh R, Mesdaghinia A, Jamshidi HR, Sayyari A, et al. NASBOD 2013: design, definitions, and metrics. Arch Iran Med. 2014;17(1):7-15. [PubMed: 24444059].
  • 12. Censuses. SCoIPah. 2014. Available from: https://www.amar.org.ir/.
  • 13. International statistical classification of diseases and health related problems (The) ICD-10. World Health Organization; 2004.Organization WH.
  • 14. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0. [PubMed: 23245604].
  • 15. Mohammadi Y, Parsaeian M, Farzadfar F, Kasaeian A, Mehdipour P, Sheidaei A, et al. Levels and trends of child and adult mortality rates in the Islamic Republic of Iran, 1990-2013; protocol of the NASBOD study. Arch Iran Med. 2014;17(3):176-81. [PubMed: 24621360].
  • 16. Mohammadi Y, Parsaeian M, Mehdipour P, Khosravi A, Larijani B, Sheidaei A, et al. Measuring Iran's success in achieving Millennium Development Goal 4: a systematic analysis of under-5 mortality at national and subnational levels from 1990 to 2015. Lancet Glob Health. 2017;5(5):e537-44. doi: 10.1016/S2214-109X(17)30105-5. [PubMed: 28363513].
  • 17. Parsaeian M, Farzadfar F, Zeraati H, Mahmoudi M, Rahimighazikalayeh G, Navidi I, et al. Application of spatio-temporal model to estimate burden of diseases, injuries and risk factors in Iran 1990 - 2013. Arch Iran Med. 2014;17(1):28-33. [PubMed: 24444062].
  • 18. Mehdipour P, Navidi I, Parsaeian M, Mohammadi Y, Moradi Lakeh M, Rezaei Darzi E, et al. Application of Gaussian Process Regression (GPR) in estimating under-five mortality levels and trends in Iran 1990 - 2013, study protocol. Arch Iran Med. 2014;17(3):189-92. [PubMed: 24621362].
  • 19. Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. Popul Health Metr. 2012;10:1. doi: 10.1186/1478-7954-10-1. [PubMed: 22226226].
  • 20. Sheidaei A, Gohari K, Kasaeian A, Rezaei N, Mansouri A, Khosravi A, et al. National and Subnational Patterns of Cause of Death in Iran 1990-2015: Applied Methods. Arch Iran Med. 2017;20(1):2-11. [PubMed: 28112524].
  • 21. R: A language and environment for statistical computing. 2014.Team R Core.
  • 22. Sergeant E. Epitools epidemiological calculators.AusVet Animal Health Services and Australian Biosecurity Cooperative Research Centre for Emerging Infectious Disease. 2009.
  • 23. Lakeh MM, Farzadfar F. Application of Gaussian Process Regression (GPR) in estimating under-five mortality levels and trends in Iran 1990-2013, study protocol. Arch Iran Med. 2014;17(3):189.
  • 24. Mahdavi S, Amoori N, Salehiniya H, Enayatrad M. Epidemiology and trends in mortality from liver cancer in Iran. Int J Epidemiol Res. 2015;2(4):239-40.
  • 25. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403-6. [PubMed: 18193122].
  • 26. Gohari K, Parsaeian M, Sheidaei A, Rahimzadeh S, Baghestani AR, Pourhoseingholi MA, et al. Equity Chasm in Megacities: Five Leading Causes of Death in Tehran. Arch Iran Med. 2015;18(10):622-8. [PubMed: 26443245].
  • 27. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5-S16. [PubMed: 15508102].
  • 28. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24(6):1667-74. doi: 10.1093/annonc/mds652. [PubMed: 23378539].
  • 29. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556-63. doi: 10.1093/annonc/mdn642. [PubMed: 19073863].
  • 30. Masoompour SM, Yarmohammadi H, Rezaianzadeh A, Lankarani KB. Cancer incidence in southern Iran, 1998-2002: results of population-based cancer registry. Cancer Epidemiol. 2011;35(5):e42-7. [PubMed: 21840285].
  • 31. Mirzaei M, Ghoncheh M, Pournamdar Z, Soheilipour F, Salehiniya H. Incidence and Trend of Liver Cancer in Iran. J Coll Physicians Surg Pak. 2016;26(4):306-9. [PubMed: 27097703].
  • 32. Shalmani HM, Noori A, Shokoohi M, Khajavi A, Darvishi M, Delavari A, et al. Burden of Hepatitis C in Iran Between 1990 and 2010: findings from the Global Burden of Disease Study 2010. Arch Iran Med. 2015;18(8).
  • 33. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-89. doi: 10.3322/caac.21349. [PubMed: 27253694].
  • 34. Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM. Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev. 2010;11(4):859-62. [PubMed: 21133591].
  • 35. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J. 2005;26(6):974-7. [PubMed: 15983686].
  • 36. Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV Coinfection Prevalence in Iran--A Systematic Review and Meta-Analysis. PLoS One. 2016;11(3). e0151946. doi: 10.1371/journal.pone.0151946. [PubMed: 27031352].
  • 37. Djalalinia S, Kelishadi R, Qorbani M, Peykari N, Kasaeian A, Nasli-Esfahani E, et al. A Systematic Review on the Prevalence of Overweight and Obesity, in Iranian Children and Adolescents. Iran J Pediatr. 2016;26(3). e2599. doi: 10.5812/ijp.2599. [PubMed: 27617064].
  • 38. Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2009;286(1):9-14. doi: 10.1016/j.canlet.2008.10.040. [PubMed: 19091458].
  • 39. Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon. 2016;16(3). e35106. doi: 10.5812/hepatmon.35106. [PubMed: 27226803].
  • 40. Qari YA, Mosli MH. Epidemiology and clinical features of patients with hepatocellular carcinoma at a tertiary hospital in Jeddah. Niger J Clin Pract. 2017;20(1):43-7. doi: 10.4103/1119-3077.180062. [PubMed: 27958245].
  • 41. Rezaei N, Amini-Kafiabad S, Maghsudlu M, Abolghasemi H. Risk factor analysis of hepatitis C virus seropositivity in Iranian blood donors: a case-control study. Transfusion. 2016;56(7):1891-8. doi: 10.1111/trf.13660. [PubMed: 27273657].
  • 42. Alter MJ, editor. Epidemiology and prevention of hepatitis B. Seminars in liver disease. New York. Copyright© 2002 by Thieme Medical Publishers; 2003. p. 39-46.
  • 43. Eskandarieh S, Hajebi A, Noroozi A, Haghdoost AA, Baneshi MR. Epidemiology of alcohol abuse in Iran. Asia Pac J Med Toxicol. 2014;3:22.
  • 44. Fernandez-Rodriguez CM, Gutierrez-Garcia ML. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. World J Gastrointest Pharmacol Ther. 2014;5(3):175-82. doi: 10.4292/wjgpt.v5.i3.175. [PubMed: 25133046].
  • 45. Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int. 2010;14(3):253-62. doi: 10.1111/j.1542-4758.2010.00437.x. [PubMed: 20491973].
  • 46. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310(9):974-6. doi: 10.1001/jama.2013.276701. [PubMed: 24002285].
  • 47. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16-27. doi: 10.1158/1055-9965.EPI-15-0578. [PubMed: 26667886].
  • 48. Esteghamati A, Keshtkar AA, Nadjafi L, Gouya MM, Salaramoli M, Roshandel G, et al. Hepatitis B vaccination coverage among Iranian children aged 15-26 months in 2006. East Mediterr Health J. 2011;17(2):93-100. [PubMed: 21735942].
  • 49. Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol. 2014;25(8):1526-35. doi: 10.1093/annonc/mdu020. [PubMed: 24631946].
  • 50. Seydel GS, Kucukoglu O, Altinbas A, Demir OO, Yilmaz S, Akkiz H, et al. Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries. Ann Hepatol Official J Mexican Assoc Hepatol. 2016;15(5).
  • 51. Hoel DG, Ron E, Carter R, Mabuchi K. Influence of death certificate errors on cancer mortality trends. J Natl Cancer Inst. 1993;85(13):1063-8. [PubMed: 8515493].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments